PYX Resources: Achieving volume and diversification milestones. Watch the video here.
Its refreshing to see posts about KNB about potential investors and wish this may continue rather than reading silly questions about whether your going to put your Cellular Goods refund money here or there especially to people you have never met. Just can't wait for Friday as they will have their own BB and we can have manful questions and debate about KNB who I reiterate have only been trading for a week.
so this share is a few days in trading and looks like some are writing it off already. Time will tell but not a week ffs
This has only been trading a few days and some volatility is expected until it settles but the PIs will bottle it before Instituntional investors as they will hoover up any cheap shares for the long game.
Excellent news and very important acknowledgment about the new strains as that’s the major global concern around current vaccines efficacy . Remember Dr Neil Graham is on board now so sit back and let him do his job with media outlets etc but be careful of the MMs and hold on to your shares. Good Luck
The purpose of the Main Market listing was to attract new international investors so any updates or reiterations are very important in showing the competence and compliance in running the company. IMO the RNS is more likely aimed at them rather than PIs .As for the Covid data results they may come on time as EXPECTED but until we have them and have confirmation they are successful lets not just dwell on words .Lets be patient but not too over confident
The real price is not falling but this was expected with so few shares in issue and milestone news due. Relatively small trades being shown going through followed by the real delayed big trades showing tomorrow .This could go on for a while even with good news but don't fall for what you see as there's bigger rewards on the horizon.
They could also be showcasing StemPrintER probably at the JP Morgan event before the Accustem IPO but at this stage they don't need to RNS it
Great news and one thing for cert is they can't go to the showcase and do a presentation with dud products
Nice deal here that shows that a takeover is always a possibility as Big Pharma are always looking to build there own pipeline
https://www.globenewswire.com/news-release/2021/01/11/2155914/0/en/Sanofi-to-acquire-Kymab-adding-KY1005-to-its-pipeline-a-human-monoclonal-antibody-targeting-key-immune-system-regulator-OX40L.html
https://www.londonstockexchange.com/news-article/OKYO/directorate-change/14817355
This may be a reason why they included in the RNS reference to Foralumab being able to withstand the new strain in Brazil. if successful then it will be more than a game changer
https://bgr.com/2021/01/06/coronavirus-mutation-south-africa-might-escape-antibodies-scott-gottlieb/
Yes I agree they may have to conduct a phase 3 trial but in between any positive results and waiting for a possible phase 3 trial final analysis IMO I can see some countries edging their bets and placing advance purchase agreements and the media noise deafening. We just need positive results first fingers crossed
If we have successful results from Brazil then IMO if the data shows that the potential benefits to protecting health clearly outweigh any potential risks, they will then apply to the FDA for emergency use authorisation just like the vaccine developers have done .If successful then it’s about scaling up maybe with a big pharma on board.
.https://www.fda.gov/vaccines-blood-biologics/vaccines/emergency-use-authorization-vaccines-explained
Yes my thoughts are with them too and hopefully if Foralumab is proven successful then it will play an important role in preventing more serious cases. Ideally im hoping if successful then its more effective without the use of dexamethasone and deliver a continuation of the potential massive upside this share offers..GLA
IMO I think they may have committed to those institutional investors of £57M at £2 of no new Tils shares issue below a fixed price say £4 as this also gives them more flexibility on the Accustem IPO opening price if they need to issue new shares for the offering but at the same time it secures the investors original investment as the will have no free shares below £2 .The good news due should easily achieve this in the next few weeks then the Accustem IPO won't be a problem if its diluted by 50% for eg
Great news - Looks like they reiterated my post from yesterday - NO NEW SHARES
Don't let the MMs take your shares off you remember no new share issues for now so whatever is going on with the share price and nasdaq shorting IMO it looks more like a way of scaring you to sell up and we are so close to news. We have to be patient and trust the company at this vital time and allow them to release news when they see it most appropriate but remember the games will continue even with good news
Admission will be through an introduction of the existing Ordinary Shares. The Company will not be issuing new shares in conjunction with the proposed Admission or the publication of the related prospectus, and has no current intention to raise capital through the issue of new shares in the UK.
https://www.investopedia.com/investing/difference-between-ipo-and-direct-listing/ The underwriter will finally determine what price this floats at bur let’s have a successful roadshow first.
https://www.theguardian.com/us-news/2020/dec/10/rudy-giuliani-leaves-hospital-drug-****tail-trump Now we just need good results from Brazil but still some good news for us towards the use of monoclonal antibodies and im sure the market will be taking note
Remember the Phase 1b/2 Clinical Trial - Crohn's Disease also keeps the Foralumab journey alive if at worst there's bad covid results. But if they are good then with both and what else they have in the pipeline this should rocket